News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 152
- Sources here
- 20
- Companies here
- 8
Search results
Stored financial headlines
Active search
152 matching headlines
Ticker or company: ESENMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Fresenius Medical Care (XTRA:FME) Stock Looks Like A Bargain Despite Weak Returns
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Fresenius Medical Care stock has recovered modestly in the short term yet is still down about 30% over the past five years, while recent valuation checks suggest …
Sharemaestro market context Price below Trend Line 52 weeks -51.0% · Next-week setup negative 3.6%Is Fresenius Medical Care (XTRA:FME) Undervalued Following Its New CEO Appointment?
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Fresenius Medical Care (XTRA:FME) has drawn fresh attention after the Supervisory Board appointed Cassie McLean as Management Board member and Chief Executive Officer …
Sharemaestro market context Price below Trend Line 52 weeks -51.0% · Next-week setup negative 3.6%Fresenius Medical Care targets ~20% 5008X conversion in 2026 while keeping operating income guidance at mid-single-digit % change
Earnings Call Insights: Fresenius Medical Care (FMS) Q2 2026 MANAGEMENT VIEW * "We continued our strong start to the year, delivering another quarter of highly profitable growth" (Chair of Management Board & CEO Helen Giza). She said operating income growth "accelerated to 23%" and …
Sharemaestro market context Price below Trend Line 52 weeks -51.0% · Next-week setup negative 3.6%Fresenius Medical Care AG (FMS) (Q2 2026) Earnings Call Highlights: Strong Profit Growth and ...
This article first appeared on GuruFocus. Revenue: Solid organic group revenue growth of 5% in Q2, with a 4% increase at constant currency. Operating Income: Increased significantly by 23% at constant currency, with growth accelerating and in line with planned phasing for 2026. Operating …
Sharemaestro market context Price below Trend Line 52 weeks -51.0% · Next-week setup negative 3.6%Fresenius Medical Care Shares Slide Despite Second-Quarter Earnings Beat
Researcher looking through microscope ©Adobe Stock Images Fresenius Medical Care (NYSE:FMS) shares fell 8.0% to €41.285 during Tuesday's trading session as investors looked beyond better-than-expected second-quarter results and focused instead on continued weakness in U.S. patient treatment volumes. Although the dialysis provider exceeded analyst …
Sharemaestro market context Price below Trend Line 52 weeks -51.0% · Next-week setup negative 3.6%IRSA Inversiones Y Representaciones (NYSE:IRS) Stock Price Crosses Above Two Hundred Day Moving Average - Here's Why
IRSA Inversiones Y Representaciones (NYSE:IRS) saw its stock price cross above its 200-day moving average, trading as high as $15.50 on Monday. The company has a consensus "Buy" rating with a $23.00 price target from analysts, while insiders own 25.06% and institutions hold 45.46% …
Sharemaestro market context Trend signal active 52 weeks +26.7% · Next-week setup positive 58.3%Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab) Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access …
FRE
main company
Sharemaestro market context
Price above Trend Line
52 weeks +1.5% · Next-week setup positive 59.6%
Fresenius Medical Care GAAP EPS of EUR0.81, revenue of EUR4.86B
* Fresenius Medical Care press release [https://seekingalpha.com/pr/20604629-fresenius-medical-care-accelerates-income-growth-to-23-percent-in-the-second-quarter-of-2026] (FMS [https://seekingalpha.com/symbol/FMS]): Q2 GAAP EPS of EUR0.81. * Revenue of EUR4.86B. MORE ON FRESENIUS MEDICAL CARE * Fresenius Medical Care: More Favorable Patient Outcomes Will Drive Growth [https://seekingalpha.com/article/4923734-fresenius-medical-care-more-favorable-patient-outcomes-will-drive-growth] * Fresenius Medical: High Yield, Utilities-Like Stock At Valuation …
Sharemaestro market context Price below Trend Line 52 weeks -51.0% · Next-week setup negative 3.6%Fresenius Medical Care appoints McLean to management board By Investing.com
Fresenius Medical Care AG has appointed Cassie McLean to its Management Board as Chief Executive Officer of the Care Delivery operating segment, effective immediately. McLean, 48, previously served as President of Fresenius Kidney Care and will now oversee the global clinic business. She replaces …
FMS
main company
Sharemaestro market context
Trend signal active
52 weeks -3.4%
Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery
BAD HOMBURG, Germany, Aug. 3, 2026 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care AG, the world's leading provider of products and services for individuals with renal disease, has appointed Cassie McLean (48) as a member of the Management Board, effective 1 August …
Sharemaestro market context Price below Trend Line 52 weeks -51.0% · Next-week setup negative 3.6%IRSA Inversiones y Representaciones SA (IRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of IRSA Inversiones y Representaciones SA (IRS), detailing its current price momentum score, support and resistance levels, and an assessment based on various technical indicators and moving averages. While the stock shows a neutral signal overall, individual indicators …
IRS
main company
Sharemaestro market context
Price below Trend Line
52 weeks +6.7% · Next-week setup positive 56.7%
Fresenius Medical Care stock trades steadily as dialysis margins and turnaround plan shape investor focus
Fresenius Medical Care stock continues to reflect the company's operational recovery in its global dialysis business, driven by steady patient volumes, improved operating performance, and margin recovery. The company reported a 5% revenue increase in Q1 2026, reaching EUR 5.00 billion, and its transformation …
FMS
main company
Sharemaestro market context
Trend signal active
52 weeks -3.4%
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
U.S. FDA and EMA acceptance for review of Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, of intravenous vedolizumab biosimilar candidate, an integrin receptor antagonist. Vedolizumab targets inflammatory bowel diseases, including moderately to severely active ulcerative colitis and Crohn's disease in adults. …
FRE
main company
Sharemaestro market context
Price above Trend Line
52 weeks +1.5% · Next-week setup positive 59.6%
IRSA Inversiones y Representaciones SA (IRS): Análisis de PE, PB y Valor Razonable
This article provides an analysis of IRSA Inversiones y Representaciones SA (IRS), focusing on its valuation score. The company currently has a valuation score of 6.55, ranking 38th out of 46 in the Real Estate Operations industry. Its current P/E ratio is 2.92, which …
IRS
main company
Sharemaestro market context
Price below Trend Line
52 weeks +6.7% · Next-week setup positive 56.7%
Understanding Momentum Shifts in (IRS)
This article analyzes Irsa Inversiones Y Representaciones S.a. (NYSE: IRS), identifying a mid-channel oscillation pattern and a strong risk-reward short setup. It details institutional trading strategies, including long, breakout, and short positions, based on AI-generated signals for various time horizons. The analysis highlights prevailing …
IRS
main company
Sharemaestro market context
Price below Trend Line
52 weeks +6.7% · Next-week setup positive 56.7%
Fresenius (XTRA:FRE) Stock May Still Be Cheap On Its 66% Run
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Fresenius SE KGaA has delivered a 65.9% return over the past three years, yet the stock still screens as undervalued on Simply Wall St's …
Sharemaestro market context Price above Trend Line 52 weeks +1.5% · Next-week setup positive 59.6%